The short version of selectivity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，C 端酰胺化 |
| 分子量 | 约 711.85 g/mol | 游离碱形式 |
| 外观 | 白色至类白色冻干粉 | 研究用材料的常见形态 |
| 溶解性 | 溶于水及 DMSO 等极性溶剂 | 建议现配现用 |
| 储存温度 | -20 °C 或更低 | 干燥、避光、限制冻融次数 |
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
The long acting insulins glargine and detemir are equally safe and effective, and do not appear much better than NPH insulin, but as they are significantly more expensive, they are not cost effective as of 2010. In those who are pregnant, insulin is generally the treatment of choice.
The basic principles of the biosynthesis of lactobacillic acid were already clarified in 1961. Lactobacillic acid, as well as other naturally occurring cyclopropane fatty acids (also abbreviated as CFA or CPFA) are formed from the corresponding unsaturated fatty acids, which have one carbon atom less, and have a cis configuration on the cyclopropane ring. The precursor of lactobacillic acid (cis-11,12-methylenoctadecanoic acid) is thus cis-vaccenic acid (cis-11-octadecenoic acid). This was demonstrated by carbon isotope14C labeled precursors. With the help of the enzymes cyclopropane fatty acid synthase, a methylene group is added to the double bond of cis-vaccenic acid. The methylene group originates from S-adenosylmethionine. The unsaturated fatty acid is not free, but is bound as an ester within phospholipids. The reaction mechanism proceeds via the formation of a carbocation. The enzyme catalyzes the reaction only with unsaturated fatty acids whose double bond has a cis configuration; the corresponding trans isomers are not converted. When the bacteria are cultivated in a batch culture, the formation of CFA occurs suddenly at a certain point in time rather than steadily increasing in concentration. At the same time, a decrease in the concentration of the unsaturated fatty acid (as a precursor) is observed. The formation of cyclopropane fatty acid occurs at the end of the exponential phase of growth or in the early stationary growth phase.
Tidepool Web — a data visualisation platform that aggregates data from a wide range of diabetes devices, including insulin pumps, continuous glucose monitors and blood glucose meters, allowing users and clinicians to review trends over time. Tidepool Mobile — a companion mobile application for logging meals, exercise and other contextual information alongside device data. Tidepool Loop — an open-source automated insulin delivery system that links a compatible continuous glucose monitor with an insulin pump to automate basal insulin dosing based on glucose readings. Tidepool Loop received FDA 510(k) clearance, making it the first FDA-cleared open-source AID application.
=== Insulin-like peptide 3 === Insulin-Like Peptide 3 (INSL3) is produced by the interstitial Leydig cells located in the adult testes. Leydig cells are responsible for steroidogenesis, the fetal Leydig cells differentiate during the development of the embryo. They produce necessary androgens for the masculinisation of organs. They also produce INSL3, which is required for the first transabdominal phase of testicular descent. INSL3 acts on RXFP2 receptors which link the testis to the inguinal abdominal wall. As a result, the testes move from the inguinal canal into the scrotum. Only mammals have a scrotum and descended testes. INSL3 measured in amniotic fluid can therefore be a biomarker for testis development, although this period differs between species.
Sources: en.wikipedia.org
=== Ser/Thr ligation === Ser/Thr ligation was introduced into protein chemical synthesis as an alternative native chemical ligation method. Serine/Threonine-ligation involves condensation of a side-chain unprotected peptide segment containing a C-terminal salicylaldehyde ester and another peptide segment with an N-terminal Ser or Thr residue. The chemoselective reaction between the peptide salicylaldehyde ester and 1,2-hydroxylamine group of Ser or Thr leads to the formation of an N,O-benzylidene acetal-linked intermediate, which undergoes acidolysis to afford a natural peptidic Xaa-Ser/Thr linkage. Ser/Thr ligation provides a complementary method for protein chemical synthesis and semisynthesis.
== Comparison to SSRIs == As SNRIs were developed more recently than SSRIs, there are relatively few of them. However, the SNRIs are among the most widely used antidepressants today. In 2009, Cymbalta and Effexor were the 11th- and 12th-most-prescribed branded drugs in the United States, respectively. This translates to the 2nd- and 3rd-most-common antidepressants, behind Lexapro (escitalopram), an SSRI. In some studies, SNRIs demonstrated slightly higher antidepressant efficacy than the SSRIs (response rates 63.6% versus 59.3%). However, in one study escitalopram had a superior efficacy profile to venlafaxine. SSRIs do not significantly increase norepinephrine, which is where SNRIs may be used for a greater variety of conditions involving norepinephrine, such as chronic pain disorders. Some additional side effects noted with SNRIs can include increased heart rate and blood pressure. Overall, most patients are able to tolerate both similarly, and their choice depends more on their symptoms, medical history, and previous response to antidepressants.
Because of the practical and, in particular, the financial scale of the program needed, the NCI decided to seek association with a pharmaceutical company, and in August 1989, it published a Cooperative Research and Development Agreement (CRADA) offering its current stock and supply from current bark stocks, and proprietary access to the data so far collected, to a company willing to commit to providing the funds to collect further raw material, isolate taxol, and fund a large proportion of clinical trials. In the words of Goodman and Welsh, authors of a substantial scholarly book on taxol, "The NCI was thinking, not of collaboration, ... but of a hand-over of taxol (and its problems)". Although the offer was widely advertised, only four companies responded to the CRADA, including the American firm Bristol-Myers Squibb (BMS), which was selected as the partner in December 1989. The choice of BMS later became controversial and was the subject of Congressional hearings in 1991 and 1992. While it seems clear the NCI had little choice but to seek a commercial partner, there was also controversy about the terms of the deal, eventually leading to a report by the General Accounting Office in 2003, which concluded the NIH had failed to ensure value for money. In related CRADAs with the USDA and Department of the Interior, Bristol-Myers Squibb was given exclusive first refusal on all Federal supplies of Taxus brevifolia. This exclusive contract lead to some criticism for giving BMS a "cancer monopoly".
=== Economic forecasts === The economic potential of AI in the UK is claimed to be substantial. PwC has estimated that AI could increase UK GDP by 10.3% by 2030, equivalent to approximately £232 billion of additional economic value, primarily through productivity augmentation in the service sector. The UK Government's own AI Opportunities Action Plan projected that AI adoption could grow the economy by an additional £400 billion by 2030. OECD estimates suggest UK labour productivity growth from AI could reach 0.4–1.2 percentage points annually over the next decade. However, realising these gains faces what McKinsey & Company has termed a "productivity paradox". Research published in February 2026 found that while AI has demonstrated substantial productivity gains in experimental settings and for specific occupations (such as software developers, writers, and consultants), UK-wide productivity data does not yet reflect an AI-driven boost, due to low adoption rates among traditional businesses, organisational inertia, and the time required for firms to restructure workflows around new technologies.
=== Oceania === The white shark population is estimated to be 2,500–6,750 individuals around eastern Australia and New Zealand. In 1999, the Australian Government gave legal protection to the species under the Environmental Protection and Biodiversity Conservation (EPBC) Act, subsequently declaring it vulnerable in 2000. Similar protections exist at the state level—some predating federal law—with New South Wales, Tasmania, and Western Australia listing the species as vulnerable, and Victoria classifying it as endangered. To bolster these protections, the federal government launched the White Shark Recovery Plan in 2002 to mandate conservation research and regulate shark-related trade and tourism. An updated 2013 recovery plan reported moderate success, with 14 of its 34 original objectives completed. A study in 2012 found that Australia's white shark population is separated by the Bass Strait into genetically distinct eastern and western populations, necessitating regionalized conservation strategies. Population declines prior to protection were driven by commercial and sport fishing, along with entanglement in beach protection netting. By 2013, incidental deaths from commercial and recreational fishing had decreased, yet the population had not fully recovered. Despite federal protections, white sharks are still killed in state-run "shark control" programs (shark culling) intended to reduce attacks. Queensland and New South Wales continue to use nets and traps, which contribute to declining numbers in eastern Australia.
Sources: en.wikipedia.org
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。
公开资料中它主要以研究用肽的形式出现，未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。
序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力，并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。
Aib 即 α-氨基异丁酸，是一种非蛋白质源氨基酸，其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。